This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Digestion === Amino acids that move beyond the terminal ileum in the body are less likely to be absorbed for use in protein synthesis. They may pass out of the body or become absorbed by bacteria, thus appearing to have been digested instead of being present in the feces. The PDCAAS takes no account of where the proteins have been digested. Similarly, amino acids that are lost due to antinutritional factors present in many foods are assumed to be digested according to the PDCAAS. This is linked with the earlier problem, as an antinutritional factor may prevent the rat's small intestines from absorbing the protein but do not deter the rat's gut bacteria from doing so. In addition, older rats show lower PDCAAS-estimated fecal digestibility compared to young rats when the protein source contains antinutritional factors. The report of 1989 did make use of existing per-amino-acid ileum digestibility values, but the requirement of pumping material out of the ileum was seen as too cumbersome. The fecal digestibility of the entire protein was adopted as a convenient approximation. It was found to be within 10% of the true amino-acid digestibility when applied to most protein sources with the notable exception of grain legumes. With beans, peas and lentils, the true digestibility of methionine, cystine and tryptophan can be much lower. In 2013, the FAO proposed changing to Digestible Indispensable Amino Acid Score, which uses per-amino-acid ileum digestibility.
=== Secondary standards === Secondary standards do not satisfy the requirements for a primary standard. A standard solution created from a secondary standard cannot have its concentration accurately known without stoichiometric analysis against a primary standard. An example of a secondary standard is sodium hydroxide, a hydroscopic compound that is highly reactive with its surroundings. The concentration of a standard solution made with sodium hydroxide may fluctuate over time due to the instability of the compound, requiring for calibration using a primary standard before use.
== Distribution and habitat == Clown loaches are native to the islands of Sumatra and Borneo in Indonesia. Clear stream environments provide the optimal habitat for clown loaches, but biannual monsoon flooding forces the fish to move into flooded flood plains, or murky or blackwater rivers or lakes, for 7–8 months of the year, and clown loaches are commonly found in the flood plains of hilly areas. Breeding adults migrate to smaller waterways to spawn annually. In its native habitat, the fish is found in water with a temperature range of 25 to 30 °C (77 to 86 °F), a pH between 5.0 and 8.0, and water hardness between 5 and 12 dH.
Sources: en.wikipedia.org
Dynamic and interactive HTML5 charting Improved and revamped scheduler (additional features over what is added in CF10 Standard) Object relational mapping enhancements The lists above were obtained from the Adobe web site pages describing "new features", as listed first in the links in the following list. CF10 was originally referred to by the codename Zeus, after first being confirmed as coming by Adobe at Adobe MAX 2010, and during much of its prerelease period. It was also commonly referred to as "ColdFusion next" and "ColdFusion X" in blogs, on Twitter, etc., before Adobe finally confirmed it would be "ColdFusion 10". For much of 2010, ColdFusion Product Manager Adam Lehman toured the US setting up countless meetings with customers, developers, and user groups to formulate a master blueprint for the next feature set. In September 2010, he presented the plans to Adobe where they were given full support and approval by upper management. The first public beta of ColdFusion 10 was released via Adobe Labs on 17 February 2012.
== SQ == sq – (s) Albanian language (ISO 639-1 code) SQ – (i) Sound Quality SQ – (i) Standard Quality sqi – (s) Albanian language (ISO 639-2 code) SQL – (i/a) Structured Query Language ("seek-well") SQS - Amazon Simple Queue Service SQUID – (p) Superconducting QUantum Interference Device SQOR – (p) Succinate:Quinone OxidoReductase, enzyme superfamily including quinone-linked succinate dehydrogenase and fumarate reductase
Only in 1901, when the Austrian Karl Landsteiner discovered three human blood groups (O, A, and B), did blood transfusion achieve a scientific basis and become safer. Landsteiner discovered that adverse effects arise from mixing blood from two incompatible individuals. He found that mixing incompatible types triggers an immune response and the red blood cells clump. The immunological reaction occurs when the receiver of a blood transfusion has antibodies against the donor blood cells. The destruction of red blood cells releases free hemoglobin into the bloodstream, which can have fatal consequences. Landsteiner's work made it possible to determine blood group and allowed blood transfusions to take place much more safely. For his discovery he won the Nobel Prize in Physiology and Medicine in 1930; many other blood groups have been discovered since. George Washington Crile is credited with performing the first surgery using a direct blood transfusion in 1906 at St. Alexis Hospital in Cleveland while a professor of surgery at Case Western Reserve University. Jan Janský also discovered the human blood groups; in 1907 he classified blood into four groups: I, II, III, IV. His nomenclature is still used in Russia and in states of the former USSR, in which blood types O, A, B, and AB are respectively designated I, II, III, and IV. American physician William Lorenzo Moss's (1876–1957) developed a blood typing technique in 1910 (popularly known as Moss system of blood typing) that was widely used until World War II.
chiasma (pl.) chiasmata A cross-shaped junction that forms the physical point of contact between two non-sister chromatids belonging to homologous chromosomes during synapsis. As well as ensuring proper segregation of the chromosomes, these junctions are also the breakpoints at which chromosomal crossover may occur during mitosis or meiosis, which results in the reciprocal exchange of DNA between the synapsed chromatids.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.